Enhanced Genomics Ltd has appointed Dietrich Stephan as chair of the board of directors to lead the biotechnology company’s strategic initiatives. The company is pioneering 3D single cell-type multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases. Dr Stephan has technical expertise in high-throughput and translational genomics and a track record in scaling, financing and leading companies. He also led genomic infrastructure programmes, such as the neuroscience genomics consortium at the US National Institutes of Health.
Copyright 2025 Evernow Publishing Ltd